Skip to main content
Clinical Trials/TCTR20190602002
TCTR20190602002
Completed
未知

Clinical Outcomes and Prognostic Factors to Predict Treatment Response in High Risk Neuroblastoma Patients Receiving Topotecan and Cyclophosphamide Containing Induction Regimen: A Prospective Multicenter Study

Phramongkutklao Hospital and College of Medicine0 sites107 target enrollmentJune 2, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
The study is an observational study and aims to evaluate the clinical outcomes and classify relevant prognostic factors to measure induction response among high risk neuroblastoma patients in Thailand
Sponsor
Phramongkutklao Hospital and College of Medicine
Enrollment
107
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 2, 2019
End Date
July 10, 2019
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Phramongkutklao Hospital and College of Medicine

Eligibility Criteria

Inclusion Criteria

  • The study’s inclusion criteria include patients less than 18 years of age who had a new diagnosis of high risk neuroblastoma stratified as per the International Neuroblastoma Risk Group Staging System (INRGSS).

Exclusion Criteria

  • Patients contra\-indicated for topotecan or receiving a diagnosis of refractory or relapsed neuroblastoma

Outcomes

Primary Outcomes

Not specified

Similar Trials